ArticleJournal of clinical immunology2012
Brief treatment with iNKT cell ligand α-galactosylceramide confers a long-term protection against lupus.
Article in Journal of clinical immunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 31 citations in OpenAlex.
- Unconventional T cells and kidney disease.Nature reviews. Nephrology · 2021Review
- Expansion of invariant natural killer T cells from systemic lupus erythematosus patients by alpha-Galactosylceramide and IL-15.PloS one · 2021Article
- Natural Killer T (NKT) Cells and Periodontitis: Potential Regulatory Role of NKT10 Cells.Mediators of inflammation · 2021Review
- Invariant NKT Cells and Rheumatic Disease: Focus on Primary Sjogren Syndrome.International journal of molecular sciences · 2019Review
- Roles of Natural Killer T Cells and Natural Killer Cells in Kidney Injury.International journal of molecular sciences · 2019Review
- Immunoporosis: A New Role for Invariant Natural Killer T (NKT) Cells Through Overexpression of Nuclear Factor-κB Ligand (RANKL).Medical science monitor : international medical journal of experimental and clinical research · 2019Article
- Repeated administration of alpha-galactosylceramide ameliorates experimental lupus nephritis in mice.Scientific reports · 2018Article
- The Janus Face of NKT Cell Function in Autoimmunity and Infectious Diseases.International journal of molecular sciences · 2018Review
- Tissue-Resident Lymphocytes in the Kidney.Journal of the American Society of Nephrology : JASN · 2018Review
- Therapeutic Potential of Invariant Natural Killer T Cells in Autoimmunity.Frontiers in immunology · 2018Review
- Dysregulated Lymphoid Cell Populations in Mouse Models of Systemic Lupus Erythematosus.Clinical reviews in allergy & immunology · 2017Review
- Transitioning from Idiopathic to Explainable Autoimmune Hepatitis.Digestive diseases and sciences · 2015Review
- Cell mediators of autoimmune hepatitis and their therapeutic implications.Digestive diseases and sciences · 2015Review
- Immunoregulation of NKT Cells in Systemic Lupus Erythematosus.Journal of immunology research · 2015Review
- Challenges in the diagnosis and management of autoimmune hepatitis.Canadian journal of gastroenterology = Journal canadien de gastroenterologie · 2013Review
- Intrinsic hyporesponsiveness of invariant natural killer T cells precedes the onset of lupus.Clinical and experimental immunology · 2013Article
- Germline deletion of β2 microglobulin or CD1d reduces anti-phospholipid antibody, but increases autoantibodies against non-phospholipid antigens in the NZB/W F1 model of lupus.Arthritis research & therapy · 2013Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
CD1d presents glycolipid antigens such as α-galactosylceramide (αGalCer) to invariant natural killer T cells (iNKT). We have reported that activated iNKTs inhibit IL-10-producing autoreactive B cells, while promoting or leaving intact the normal B cell responses, making iNKT modulation an attractive therapeutic modality. Here, we report that a brief treatment of young lupus-prone (NZB/NZW)F1 (BWF1) mice with two injections of αGalCer conferred a long-term protection against lupus. Long-term repeated administrations of αGalCer, however, afforded no clinical benefit. These disparate clinical effects correlated with iNKT responsiveness. While a brief treatment with αGalCer enhanced iNKT responses upon in vitro recall, the long-term αGalCer treatment resulted in reduced iNKT responses in BWF1 mice. The improvement in disease with αGalCer treatment was associated with the reduced IL-10 production. Furthermore, iNKTs directly inhibited IL-10-secreting cells in vivo in reconstituted SCID mice and inhibited IL-10-secreting B cells in vitro in co-cultures. Thus, a brief treatment with a CD1d-binding glycolipid enhances iNKT responses, reduces IL-10 production, and delays the onset of lupus, whereas long-term repeated treatments induce marked iNKT hyporesponsiveness and do not affect disease outcome in BWF1 mice. Identifying glycolipid regimens that can modulate iNKT responsiveness will have important implications for developing iNKT-based therapies for autoimmune diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.